Stephens Consulting’s RxSight RXST Stock Holding History

Stephens Consulting’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$379	–	1840
2025 Q1	$379	Buy	+15	New	+$446	﹤0.01%	1142

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stephens Consulting's RXST Position: Q2 2025 in Review

Stephens Consulting sold out of RxSight (RXST) in Q2 2025, closing a stake of 15 shares — an estimated $379 sold.

Stephens Consulting first reported a position in RXST in Q1 2025 and held it in 1 quarter. The position peaked at $379 in Q1 2025. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

Stephens Consulting reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 15 RxSight shares in Q2 2025, an estimated $379.
Stephens Consulting first reported a position in RxSight in Q1 2025 and held it in 1 quarter.
Stephens Consulting's RxSight position peaked at $379 in Q1 2025.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.